摘要
目的观察白蛋白结合型紫杉醇治疗晚期难治性乳腺癌的效果。方法选取2018年4月-2019年7月广东省阳江市人民医院收治的晚期难治性乳腺癌患者108例,根据治疗方法不同分为试验组58例与对照组50例。对照组予以常规治疗,试验组予以白蛋白结合型紫杉醇治疗。比较2组患者的肿瘤总缓解率及不良反应发生情况。结果试验组患者肿瘤总缓解率为86.21%明显高于对照组的56.00%(χ^2=12.213,P=0.000),不良反应发生率为13.79%低于对照组的32.00%(χ^2=5.150,P=0.023)。结论白蛋白结合型紫杉醇治疗晚期难治性乳腺癌具有较好效果。
Objective To observe the effect of albumin-bound paclitaxel on advanced refractory breast cancer.Methods 108 cases with advanced refractory breast cancer admitted to People’s Hospital of Yangjiang from April 2018 to July2019 were selected.According to different treatment methods,58 cases were divided into test group and 50 cases in control group.The control group was treated with routine treatment,and the experimental group was treated with albumin-bound paclitaxel.The total tumor remission rate and adverse reactions were compared between the two groups.Results The total tumor remission rate of the test group was 86.21%,significantly higher than 56.00%in the control group(χ2=12.213,P=0.000),the incidence of adverse reactions was 13.79%,lower than 32.00%in the control group(χ2=5.150,P=0.023).Conclusion Albumin-bound paclitaxel has a good effect in the treatment of advanced refractory breast cancer.
作者
郑彩红
唐之雅
刘挺
ZHENG Caihong;TANG Zhiya;LIU Ting(People's Hospital of Yangjiang,Guangdong Province,Yangjiang 529500,China)
出处
《临床合理用药杂志》
2020年第13期20-21,共2页
Chinese Journal of Clinical Rational Drug Use
关键词
白蛋白结合型紫杉醇
乳腺癌
晚期难治性
肿瘤总缓解率
不良反应
Albumin-bound paclitaxel
Breast cancer,advanced refractory
Total tumor remission rate
Adverse reactions
